OR WAIT 15 SECS
The rates and severity of Clostridium difficile infection (CDI) may be impacted by several factors, including antimicrobial use, other drug-prescribing factors, infection control practices, and the presence of a new strain of C. difficile that is more resistant to fluoroquinolones and associated with higher rates of morbidity and mortality. It is crucial for healthcare professionals to be aware of these factors and apply evidence-based practices for the prevention, diagnosis, and treatment of CDI.
To address the need for current education on CDI, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture titled, "Clostridium difficile Infection: Tracking a Virulent Pathogen." The content of this virtual lecture is based on a live symposium that took place on June 10, 2009, during the 36th Association for Professionals in Infection Control and Epidemiology (APIC) annual conference. This activity is supported by an educational grant from ViroPharma Incorporated.
Faculty for this program are experts in infection control and gastroenterology, including Stuart Johnson, MD, DTM&H; Dale N. Gerding, MD, FACP, FIDSA; Ciaran P. Kelly, MD; and Keith S. Kaye, MD, MPH.
Healthcare professionals can visit http://www.RMEI.com/CDI079VL to access this complimentary continuing education virtual lecture.